With years of experience in the business of science and training as a scientist as well as in business management, Cerylid Biosciences CEO Dr Jackie Fairley is well equipped to give advice on the pitch, whether it's in the elevator or at a venture capital forum. [ + ]

It used to be that biology students would run a mile from anything that smacked of computing. Now, with bio-IT touted as an indispensable element of the life sciences, what's changed? [ + ]

You can't pick up a general article about proteomics without reading somewhere in the story: "The word 'proteomics' was coined by Marc Wilkins, then a PhD student in Keith Williams' lab at Macquarie University in 1994..." [ + ]

The NSW government launched its BioFirst program in September last year. Like most other governments' biotech programs, the NSW initiative involves several government departments. [ + ]

Biotech in NSW doesn't appear to depend on fancy government packages, but new infrastructures are changing the face of bio in the First State. [ + ]

In the last month, three of Australia's most experienced listed biotechs have endured roller coaster rides on the stock market, in the case of all three because of upheaval at the board level. [ + ]

Just over a month ago, with his company on the verge of big new international deals, Peptech managing director Stephen Kwik agreed to leave the company so the board could replace him with a CEO with scientific background and commercial expertise. [ + ]

Scientist-turned-financier Dr Kevin Healey is one of an elite group which has used its life science credentials as a springboard to make a splash as venture capitalists. [ + ]

Queensland is cooking up a thriving biotech sector by successfully blending half a dozen hard-to-find ingredients. [ + ]

Kate Parker helped nurture Invest Australia through its initial growth spurt 18 months ago. Now with the Commonwealth government agency growing again, restructuring and on the brink of becoming independent, Parker is leaving. [ + ]

Cash-strapped biotech startups are increasingly rewarding their staff with shares in the company. [ + ]

One of the spin-offs of Australia's burgeoning biotech sector is an increasingly competitive recruitment sector. [ + ]

Distributed processing gets an updated look as vendors go for the grid: In early 2000, Cereon Genomics had a serious situation on its hands: It was running out of computing power. [ + ]

Stan Yakatan, "US venture capital raising guru" and strategic biotechnology adviser to the Victorian government, sits at a table in The Westin Melbourne's Allegro restaurant surrounded by breakfast, documents and five chairs intermittently filled and vacated biotech movers and shakers. [ + ]

Venture capitalists complain they are finding it ever-tougher to coax fresh funds from investors. Yet paradoxically, the total Australian pool of life science risk capital stands at record levels. [ + ]